Trial Profile
Optimal treatment of drug resistant hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxazosin (Primary) ; Bisoprolol; Spironolactone
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms PATHWAY-2
- 16 Feb 2016 Results published in the Annals of Internal Medicine
- 26 Jul 2015 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 15 Nov 2014 Planned End Date changed from 30 Jun 2015 to 21 Jul 2014 according to United Kingdom Clinical Research Network record.